



Supplementary Fig 1

Figure shows Kaplan-Meier survival rate in the preliminary experiment. Oxaliplatin (OXL) or glucose was intravenously administered on day -14, -11, -8, -5, -2, 1, 4, 7, 10, 13, 17, 20, 23, 26, 29, 32, 35, 38, 41 and 44 (every 3 days). Phosphate buffered saline (PBS), recombinant human lactoferrin (rhLf) or recombinant human lactoferrin Fc fusion (rhLf-Fc) was intraperitoneally administered on day 0, 7, 14, 21, 28, 35 and 42 at the dose of 100 mg/kg. The first mouse to die was confirmed 14 days after the start of drug administration in the OXL + rhLf group. The survival rate showed remarkable decreasing at the 21st day in the OXL + rhLf group, and the 28th day in the OXL + rhLf-Fc group, respectively.